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T
he survival of people diagnosed 
with HIV/AIDS dramatically 
improves with access to 
highly active antiretroviral therapy 
(HAART). Such therapy employs 
a combination of antiretroviral 
agents—protease inhibitors (PIs), 
nucleoside reverse transcriptase 
inhibitors, non-nucleoside reverse 
transcriptase inhibitors, nucleotide 
reverse transcriptase inhibitors, 
and fusion inhibitors—to suppress 
viral replication, and, thus, reduces 
the likelihood of developing HIV 
mutations that could lead to the 
development of drug-resistant viral 
strains. HAART also prevents further 
viral destruction of the cellular 
immune system, thereby, allowing for 
increases in the level of CD4+ cells, 
which improves the immunologic 
response to opportunistic infections. 
However, 
suboptimal 
treatment 
adherence has 
been associated 
with virologic, 
immunologic, and 
clinical failure. In 
this essay, I look 
critically at the 
issue of adherence, 
and argue that, 
to address causes 
of incomplete 
adherence, we 
need to combine 
both quantitative 
and qualitative 
methodologies. 
These 
methodologies must 
be grounded in 
an understanding 
of adherence as 
a biological and 
social process 
that changes with 
time, and must be 
framed within an 
analysis of access 
to health care and 
medications.
Adherence and 
Drug Resistance
A consensus exists 
that in order 
to achieve an 
undetectable viral 
load and prevent the development of 
drug resistance, a person on HAART 
needs to take at least 95% of the 
prescribed doses on time [1]. For many 
people, this means taking a regimen of 
three antiretrovirals twice per day—on 
both occasions, they are usually taking 
several pills [2]. An increasing number 
of studies show that the relationship 
between adherence and resistance 
is drug speciﬁ  c [3]. Although the 
suggestion that this relationship follows 
a bell-shaped curve has existed since just 
after the introduction of HAART [4], 
there is increasing evidence that drug 
resistance is highest among those taking 
70%–80% of regimens containing a 
nonboosted PI (i.e., regimens with 
no combined ritonavir), and among 
those with intermittent or single-dose 
regimens of non-nucleoside reverse 
transcriptase inhibitors (including when 
nevirapine is used once to prevent 
mother-to-child transmission of HIV) 
or with poor adherence to these types 
of antiretrovirals. Ritonavir-boosted 
PIs (a full dose of a PI combined with 
ritonavir to increase the blood levels of 
the former) confer limited resistance, 
regardless of one’s level of adherence 
[3]. 
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Given the relevance of treatment 
adherence to improving life expectancy 
and preventing the spread of drug-
resistant strains, many studies have 
attempted to predict causes of 
nonadherence in order to design 
strategies that reduce the number 
of missed doses. Except for some 
factors that have been associated with 
incomplete adherence in various 
settings, such as depression [5,6] 
or illegal drug use [7], study results 
are often inconclusive and do not 
yield comparable results—often due 
to conceptual and methodological 
differences among research protocols. 
Methodologically, there is growing 
agreement that patients’ self-
assessments of adherence—through 
interviews or self-administered 
questionnaires—show signiﬁ  cant 
correlation with viral load tests [8–10], 
whereas estimations by their health-
care providers often lead to invalid 
results [11]. 
Despite the current shortcomings in 
predicting who is more likely to miss 
doses of antiretroviral therapy (ART), 
the issue of adherence has become 
extremely important when setting 
priorities for allocating resources to 
ﬁ  ght AIDS in poor countries, where 
the majority of  people who are HIV 
positive live. Some commentators have 
argued that adherence barriers are 
insurmountable in poor settings, so we 
should be cautious in delivering ART 
to these populations—a claim that 
is not grounded in evidence. In fact, 
adherence in poor settings is proving 
to be equal to, or even higher than, 
adherence in developed countries [12–
17]. Furthermore, the argument about 
insurmountable adherence barriers in 
poor settings has also been challenged 
because it creates an unjustiﬁ  able 
double standard [11]—ART is not 
withheld from wealthy settings on the 
basis that many patients will skip doses.
Adherence as a Biosocial 
and Dynamic Phenomenon
A biosocial approach to adherence 
relies on the dynamic analysis of the 
clinical and social course of disease 
and the continuous interaction of 
biological and social processes over 
time [18–21]. The study of pathology 
embedded in social experience 
captures a series of distal and proximal 
factors acting together—such as not 
seeking treatment for undesirable side 
effects due to lack of money to travel 
to a health center or purposely missing 
doses when one is asymptomatic to 
pretend that AIDS is not a concern. 
These factors shape the everyday life 
of patients, while patients internalize 
them and use them to provide meaning 
to their disease experience. 
Years ago, before the advent of AIDS, 
anthropologists had noted that the 
introduction of effective therapy for 
a particular disease may profoundly 
alter the social interpretations of that 
disease [18,22]. Exposure to AIDS 
in Haiti, in the 1980s, generated 
cultural models of its etiology and 
expected course [19,23,24], which 
aimed to provide meaning to otherwise 
unknown phenomena—often locally 
interpreted in terms of jealousy and 
curse. Likewise, the social experience 
of AIDS in rural Haiti is also deeply 
affected by the advent of effective 
therapy, as preliminary data suggest 
that the introduction of quality HIV 
care can lead to a rapid reduction in 
stigma, with resulting increased uptake 
of testing [21]. 
Within the changing context 
in which disease may take place, 
adherence level is likely to change as 
biological and social circumstances, 
and interpretations of them, unfold. 
In Brazil, a boy and a girl living in 
a support house for children and 
adolescents orphaned by AIDS or living 
with HIV explained why, upon feeling 
well, they had started to delay the 
morning dose of antiretrovirals until 
the afternoon: “[The schedule] doesn’t 
matter; you can take them any time, as 
long as you take them” [25]. Until they 
started HAART, they had both suffered 
several opportunistic infections and, 
at times, had been at the brink of 
death. Their incomplete adherence 
to the regimen was, in part, a lack of 
understanding about the importance of 
not missing doses—but, fundamentally, 
it was a strategy they had developed as 
Box 1. Biosocial Variables for 
Understanding Adherence to 
ART
Socioeconomic Factors
• Poverty and inequality
• War, political violence
• Cost of medications
• Cost of CD4+ counts, viral load
• Transportation costs
• Cost of missing days from work
• Cost of food and safe water
• Costs associated to changes in lifestyle
• Other costs
Health-Care System
• Health-care infrastructure
• Drug stock shortages
• Financing mechanisms (including user 
fees)
• Quality of relationship with health-care 
providers
Social Capital
• Kinship patterns
• Networks of social support
• Social status
• Homelessness, incarceration
Cultural Models of Health and Disease
• On etiology and transmission
• On health-care providers and healers
• On cure
• On efﬁ  cacy and toxicity of drugs
• On sick role
Personal Characteristics
• Age
• Sex and gender
• Ethnic group
• Education
• Occupation
• Household composition
• Substance abuse
• Physical disabilities
Psychological Factors
• Self-esteem and motivation
• Mental health conditions
Clinical Factors
• Immunological or clinical stage of HIV 
disease
• Occurrence and severity of 
opportunistic infections
• Side effects (desirable and undesirable)
• Symptomatology at onset of treatment
• Effect of pregnancy or lactation
Antiretroviral Regimen
• Number of drug regimens per day
• Number of pills per regimen
• Therapeutic class composition of drug 
regimen
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an act of deﬁ  ance against the rules of 
the support house, and probably to feel 
more like the children who were HIV 
negative who also lived there and were 
not taking daily medications [25]. By 
delaying the morning dose, they were 
providing their lives with a sense of 
normalcy, which had otherwise been 
characterized by orphanhood and 
chronic disease since early age, while 
acting out in protest.
By any account, these children would 
be classiﬁ  ed as having incomplete 
adherence or, plainly, as nonadherent. 
Yet to improve their adherence, how 
helpful is it to know that they are 
not taking all their medications on 
time without understanding why? 
Could their nonadherence really be 
understood without analyzing the 
life trajectories of these children and 
their social context? Some studies 
approaching ART adherence within a 
dynamic framework have relied on a 
biosocial approach, providing a rich 
context in which taking medications 
occurs and evolves [7,9,26–28]. Other 
studies, while having observed that the 
level of adherence is not a static value, 
have remained mostly biomedical, 
examining the impact of side effects 
[29] or substance abuse [30], and 
have been devoid of the complexity 
of biosocial interactions and their 
changing nature, as in the case of the 
Brazilian children. 
The study of life histories of 
patients—a standard qualitative 
method of ethnographic research—and 
of the interactions of social experience 
with illness episodes allows us to 
generate associations between the 
clinical and the social course of disease, 
including such themes as stigma, 
health-seeking behavior, or adherence 
to therapy. These associations, 
which are often drawn from a small 
sample of patients, can be validated 
by larger, statistically representative, 
epidemiological studies designed to 
include variables reﬂ  ecting the social 
context of patients. For example, the 
effect of adipose tissue alterations 
(lipodystrophy)—a common side effect 
of PIs—on adherence to ART has 
often been studied without considering 
local patterns of ideal weight and body 
shape for women and men at different 
ages, and existing variations of these 
ideals related to the social position of 
patients. This lack of consideration for 
local patterns may explain why some 
studies arrive at opposite results—
dystrophic weight gain as a barrier to or 
as an enhancer of adherence [29,31]. 
The effect of adherence on weight gain 
seen in patients on ART, as a result of 
a reversal of the disease process and 
general clinical improvements, should 
also be analyzed in relation to these 
social ideals. In Senegal, for example, 
where weight gain is a symbol of good 
health, such weight gain has been 
shown to increase adherence [26]. 
Most research studies on adherence 
to ART share the basic understanding 
that patients are adherent when they, 
after agreeing to the recommendations 
of a health-care provider [32], take 
the prescribed medications in a timely 
manner. However, an overemphasis on 
pill counting as a sum of discrete events 
limits our understanding of adherence 
as a complex process embedded in the 
clinical and social course of AIDS, as the 
case of the Brazilian children shows. An 
approach to adherence that combines 
both biological and social knowledge—a 
biosocial approach—and that relies 
on qualitative and quantitative 
methodologies is more likely to move 
us closer to a better understanding of 
adherence and, eventually, to improving 
adherence to ART. 
Poverty and Adherence
Partly because the introduction of 
ART in poor settings is recent, and 
partly because biomedical research 
rarely examines the social context in 
which patients live, there is a dearth 
of information on the direct effect 
of poverty on ART adherence. Most 
studies conducted in poor settings 
overlook how direct and indirect 
economic burdens borne by patients 
affect their ability to access a steady 
supply of antiretrovirals and take them 
on time. Such burdens may include 
the cost of missing work, the cost of 
elder or child care during medical 
visits, the cost of transportation to a 
health center, the cost of user fees, or 
the cost of tests and supplies. Although 
these costs may seem minimal to health 
professionals and decision makers, 
bearing these costs often translates into 
difﬁ  cult household decisions about who 
eats, who works, or who goes to school. 
Taking medications in a timely manner 
may also require the challenging tasks 
of obtaining food and safe water, or of 
readjusting food intake to ﬁ  t the drug-
regimen schedule. 
Despite the difﬁ  culties in overcoming 
these obstacles, the inability of a person 
living in poverty to obtain and take 
medications after initiating therapy 
is often labeled “noncompliance” 
or “nonadherence”—as has often 
occurred with tuberculosis patients 
[33,34]—and categorized as patient-
related characteristics, ignoring social 
and economic causes or failures on 
the part of public-health interventions 
to address those causes [35]. Some 
studies conducted in Côte d’Ivoire 
[36], Senegal [28,37,38], and Botswana 
[39,40] show that user fees not only 
deter people from accessing AIDS 
care but also create an obstacle 
to treatment adherence. In other 
contexts where ART is free, such as 
Costa Rica, transportation costs have 
been associated with lower adherence 
[41]. The argument that patients 
would not value free drugs, or that 
free treatment might be humiliating 
for patients, are not borne out by 
higher adherence rates when drugs 
are free, such as in a comprehensive 
AIDS program in rural Haiti [14] or 
in Cuba [17], or when user fees are 
lowered, such as in Senegal [37,42]. 
Indeed, variations of directly observed 
therapy (DOT) for the delivery of 
ART (known as DOT-HAART) have 
proven useful in introducing complex 
multidrug regimens in poor settings 
lacking health-care infrastructures. In 
rural Haiti, for example, support for 
patients receiving DOT-HAART from 
community health workers improves 
rates of adherence [14]. 
As adequate and equitable access to 
comprehensive AIDS prevention and 
care are introduced, optimal adherence 
could be achieved if the multiple causes 
that shape patients’ adherence are 
analyzed within their social context—
including those related to the ﬁ  nancing 
of health-care systems, and particularly 
cost-recovery mechanisms. 
A Biosocial Approach to Causes of 
Nonadherence: The Way Forward
The use of a biosocial framework 
grounded in the lived experience of 
people diagnosed with AIDS is essential 
to understanding adherence, the way 
adherence changes over time, and 
the reasons for nonadherence. Often 
times, particularly in poor settings, 
these reasons will be found outside the 
individual responsibility of patients. 
Addressing adherence may require 
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providing social support to patients, 
lowering or eliminating user fees, 
bringing health-care workers closer 
to patients, opening health centers 
focused on patients’ competing 
demands to survive, improving drug 
procurement strategies, or creating 
mechanisms for lowering the cost of 
drugs and lab tests. In many cases it 
will mean improving and investing in 
primary health care, public hospitals, 
and referral networks, or in incentives 
to recruit and retain health-care 
workers committed to serving their 
patients. Given this complexity, 
the possibility of advancing the 
understanding of the multifaceted 
causes of nonadherence needs to 
be analyzed within its larger social, 
economic, and political context.
Box 1 shows the main biosocial 
variables needed to analyze adherence 
to ART deﬁ  ned within eight broad 
categories: socioeconomic factors, 
health-care system, social capital, 
cultural models of health and 
disease, personal characteristics, 
psychological factors, clinical factors, 
and antiretroviral regimen. Most 
clinical studies have focused on the last 
four areas, which are easier to measure 
quantitatively but which do not account 
for the larger social context. Although 
clinical epidemiological studies are 
essential to ﬁ  nding associations between 
drug regimens and adherence—and, 
depending on the method chosen, 
to establishing causality—a biosocial 
approach that combines quantitative 
and qualitative methodologies is 
necessary to bridge the current gap 
in knowledge on adherence to ART. 
Only by understanding the complicated 
interplay between the clinical and 
social factors that affect adherence to 
ART can we hope to overcome the real 
causes of nonadherence.  
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